Company ProfilePremium

Green Fresh Biotechnology Company Limited (formerly Green Future Food Hydrocolloid Marine Science Company Limited)

Company Profile Analysis

綠新生物科技有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Green Fresh Biotechnology Company Limited - Company showcase

Year Founded & Workforce

1999

1,030 Employees

Green Fresh Biotechnology Company Limited logo

Green Fresh Biotechnology Company Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Green Fresh Biotechnology Company Limited Overview

Green Fresh Biotechnology is a vertically focused, Fujian-based manufacturer of seaweed- and plant-derived hydrocolloids: agar-agar, refined and semi-refined carrageenan, konjac gum, and custom blended texturant systems. It sells to food processors and trading houses in roughly 50/50 domestic and export proportions. A Frost & Sullivan report commissioned by the company (March 2025) ranks it first in China by sales value, volume and share among producers of agar-agar and refined/semi-refined carrageenan, and as the largest global manufacturer of these products in 2020–21 and 2023–24. Its 27,390-tonne design capacity spans Zhangzhou, Quanzhou, Hubei (konjac), Xiamen (agarose microspheres) and Indonesia (semi-refined carrageenan). The equity story has moved from a 2022 commodity-price windfall, through a 2023 inventory write-down loss, to a thin-margin, highly levered recovery. Management is reframing the group as a "biotechnology" company through higher-value blends, quick-dissolve agar, agarose for life sciences and a nascent 100% biodegradable seaweed-film business.


Company's own description (FY2025 AR, Corporate Overview)

The FY2025 AR describes the company as a global leader in the technical development and manufacturing of "all-natural performance materials". Its main products are:

  • agar-agar and carrageenan made from naturally bred seaweed;

  • konjac gum made from naturally bred konjac;

  • blended products with extended functions created by combining different colloids and gums, together with professional solutions built on them.

The primary applications are processed foods: processed meat, confectionery, dairy, sauces, bakery, pet food and, increasingly, flavoured tea beverages. Beauty and household uses include 100% biodegradable face masks and gel air fresheners, and the company is entering plastic-alternative wrapping and soil film. Agarose and agarophyte products, made through more complex processes, serve as laboratory culture media and electrophoresis media for genetic sequencing.

The company also describes itself as a long-term partner to customers, both in raw-material supply and in parts of their product development. It positions this co-development as a deliberate strategy to secure orders (FY2024 ARA; FY2025 ARA, "Business Development Strategy").

Independent characterisation

In substance, Green Fresh is a B2B specialty-ingredient processor operating at the commodity end of the texturant value chain.

Earnings drivers: Roughly 73–85% of revenue (73.3% in FY2025; 85.8% in FY2023) comes from two seaweed-derived extracts, carrageenan and agar. Their prices are set largely by the global price of red seaweed (Eucheuma/Kappaphycus for carrageenan; Gracilaria/Gelidium for agar). The FY2022–FY2025 record shows that group earnings are a function of the seaweed price cycle and inventory timing more than of volume growth.

  • FY2022: rising seaweed prices produced record gross profit of RMB384.1m.

  • FY2023: falling seaweed prices forced a RMB142.4m inventory write-down and a loss.

  • FY2024: release of that provision on sale lifted margins.

  • FY2025: continued price deflation compressed carrageenan margins again.

Higher-value tier: Blended products, quick-dissolve agar, konjac and agarose microspheres carry higher or more stable margins. Together they were about 25% of revenue in FY2025.

Business model and revenue model

DimensionCharacterisation (FY2025 basis)
Revenue model~100% product sales, recognised at a point in time on delivery (FY2025 ARA note 3). No subscription, licensing or service revenue is disclosed.
PricingContract prices net of VAT. Credit terms up to 180 days. Contract liabilities (advances) of RMB7.2m at FY2025.
Product vs service mixProduct ~100%. Application/formulation support is bundled, not separately billed.
Value chain positionMidstream: buys dried seaweed and konjac (top-5 suppliers 53.0% of purchases; largest 16.6%, FY2025) → extraction/refining → powders and blends → sells to food manufacturers and trading companies.
Customer typesFood manufacturers (meat, dairy, confectionery, bakery, beverages, pet food), ingredient traders/distributors, cosmetics/household manufacturers, and life-science users (agarose). Top-5 customers 24.9% of revenue; largest 8.0% (FY2025).
End-marketsProcessed food (dominant), beverages (tea "chewing contents"), pet food, personal care (masks), household (air-freshener gels), biomedical/lab (agarose), packaging/agriculture (algae membrane, nascent).
GeographyChinese Mainland 48.1%; overseas 51.9% (Europe 26.0%, Asia ex-China 17.9%, South America 5.3%, North America 2.3%, Africa 0.5%) — FY2025.

Strategy

Stated strategy themes (FY2024 and FY2025 ARAs and ARs)

  1. "Long-term partner" model. Embed in customers' raw-material supply chains and co-develop applications to secure orders.

  2. Product-technology upgrading. Shift the mix toward higher-technology, higher-margin products: blended solutions, quick-dissolve agar, deep-processed bakery carrageenan, konjac fibres and agarose/microspheres.

  3. Application diversification. Extend beyond food into household (gel air fresheners), skincare (biodegradable masks), and plastic alternatives (algae membrane wrapping and soil films). Management frames this as a decarbonisation opportunity "for the coming decades".

  4. Geographic diversification of production. Expand and upgrade PT Hongxin in Indonesia for cost advantage, proximity to seaweed resources and potential tax efficiency on sales originating from Indonesia.

  5. Overseas sales-network build-out. Add overseas sales representatives and trade-show presence (S&D +25.7% in FY2025), particularly for blended products.

  6. Rebranding as biotechnology. The 2025 name change was justified by seaweed's carbon-negative growth profile and its role as an alternative to fossil-fuel-based materials.

  7. Dividend continuity. A "target dividend payout each year after considering available resources" (HK1.2c in both FY2024 and FY2025), paid out of share premium.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Blue Ocean algae-membrane recapitalisation with local state-linked investor31 Oct 2024Xinwan Investment (Longhai District) up to RMB63.85m; group injects RMB27.77m; group stake 46.68%Completed (registration of capital injection)
Certification programme for biodegradable filmMay–Dec 2025FDA food-contact assessment; SGS Bio-Based and No Plastic; home compostabilityAchieved; commercial revenue not disclosed
Beverage "chewing contents" capacityAug 2024 – Feb 2026HK$6.5m allocated from placement; HK$4.8m used by end-FY2025In progress
Corporate rebrand to Green Fresh BiotechnologyJun–Jul 2025Name and stock short name changeCompleted
PT Hongxin facility enhancementOngoingQuality and cost upgrades; capacity expansion planned, internally fundedOngoing (capex RMB47–48m p.a. group-wide)
Competitive pricing strategy for carrageenan1H2026Volume-led share recapture; carrageenan revenue +49%Delivered revenue; margin compressed to 14.2%
Inventory turnover and cost-saving measures2,026Part of the going-concern mitigation planInventory −7.7% in 1H2026
Covenant managementDec 2025 onwardWaivers on RMB125.6m; continued facility renewalsOngoing

Medium-term targets and guidance

No quantitative medium-term financial targets or formal guidance (revenue, margin, ROE, leverage) are published. Management's qualitative outlook (FY2025 AR) expects:

  • carrageenan prices to "bottom out and gradually rise" with the business cycle;

  • PRC sales to improve;

  • the blended-product uptrend to continue.

Products & Services

Prices are not publicly disclosed for any product; all are sold B2B on contract. Brand names for individual SKUs are not disclosed in the filings reviewed.

Agar-agar segment

ProductDescription & capabilitiesTarget customersLaunch / milestoneNotes
Conventional agar-agar (food grade)Gelling agent from red seaweed (Gracilaria/Gelidium); heat-stable gels; soluble dietary fibreJelly, confectionery, desserts, bakery fillings, health foodsAgar lines since the 2012 Lvqi mergerCovered by GB1886.239-2016, which the group helped draft
Quick-dissolve agar-agarDeep-processed agar that dissolves at lower temperature/faster; used in yoghurt and dairyDairy manufacturers (China)Marketed via Lvqi Trading (Shanghai) from 2018; +capacity 2019Management repeatedly cites it as one of the highest-margin products (FY2021–FY2025 ARs)
AgaroseHigh-purity agar fraction for laboratory culture media and electrophoresis in genetic sequencingLife-science labs, diagnostics, reagent distributorsIPO proceeds earmarked for 50 t agarose capacity (Longhai)Small revenue; not separately disclosed
Agarose microspheres / agar gel microspheresSeparation medium (chromatography) for biomedical production processesBiopharma process usersProduction commenced 2022; Xiamen Sanji base, 10 t/yrHighest-technology product; revenue not disclosed
Agarophyte productsProcessed agarophyte seaweed materialsIndustrial / labIPO plan (200 t)—

Carrageenan segment

ProductDescription & capabilitiesTarget customersLaunch / milestoneNotes
Refined carrageenan (kappa/iota/lambda grades)Thickener, gelling agent, stabiliser; water retention in meat; suspension in dairyProcessed meat, dairy, confectionery, sauces, pet food; European and Asian food majors and tradersLvbao since 2001; Green Fresh (Fujian) since 2007FY2025 refined carrageenan volume −10.7%, ASP −5.1%
Refined iota carrageenanElastic gels, freeze–thaw stabilityDairy desserts, meatIPO plan for 180 t/yr—
Semi-refined carrageenan (SRC/PES)Lower-cost alkali-treated seaweed carrageenanPet food, meat, industrial usersPT Hongxin (Indonesia) acquired Apr 2021, 4,300 t/yrCost and seaweed-proximity advantages
Deep-processed carrageenan for bakeryApplication-tailored grades for bakeryBakery manufacturersHighlighted FY2023–FY2025Cited as a margin-enhancing growth product

Konjac segment

ProductDescription & capabilitiesTarget customersLaunch / milestoneNotes
Konjac gum (glucomannan)High-viscosity soluble fibre; gelling with carrageenan/xanthanHealth foods, low-calorie foods, jellies, plant-based meat textureShiyanhaiyi since 2012; +1,500 t Fujian line 2019FY2025 revenue +54.3%; margin 14.9%
Konjac blends for plant-based meatGives meat-like mouthfeelAlt-protein producersCited FY2021 AR—
OEM fibre-rich health foodsOEM manufacturing of fibre products for personal consumptionHealth-food brandsStarted per FY2021 ARScale not disclosed

Blended products segment

ProductDescription & capabilitiesTarget customersLaunch / milestoneNotes
Custom blended texturant systemsReady-to-use mixtures of carrageenan, agar, konjac and other gums tailored to function (gel strength, water binding, syneresis control)Meat processors, dairy, beverages, desserts; overseas networks being builtLvbao blends since 2000s; 3,300 t/yr capacitySales-volume CAGR of more than 20% over 2021–2025 (FY2025 AR); revenue CAGR 17% over 2021–2024 (FY2024 ARA)
"Chewing contents" for flavoured beveragesReady-to-use gel pieces/inclusions for tea drinksNew-style tea chains and beverage makersHK$6.5m of 2024 placement proceeds earmarked; HK$1.7m unused at end-FY2025Trend-linked, China-centric

Others / non-food and new materials

ProductDescription & capabilitiesTarget customersLaunch / milestoneNotes
Gel-type air freshenersCarrageenan/agar-based gel matricesHousehold products makersDeveloped FY2023–FY2025—
100% biodegradable face-mask substratesSeaweed-based mask sheetsCosmetics brandsDeveloped FY2023–FY2025—
100% biodegradable algae membrane (wrapping film, seasoning/food packing film, soil film)Seaweed-based plastic alternative; FDA food-contact assessment passed (May 2025); SGS 100% Bio-Based (Aug 2025) and No Plastic (Oct 2025) certifications; home-compostability compliance (Dec 2025)Food/seasoning packaging, cosmetics packaging, agricultural mulchBlue Ocean set up Jul 2023; HK$16.2m of the 2024 placement fully deployedPre-commercial scale; revenue not disclosed
Seaweed / algae powder tradingTrading of seaweed powderVarious"Others" segmentRMB14.8m in FY2025

Financial Narrative

Income statement

Sources: FY2022–FY2025 from the FY2023, FY2024 and FY2025 ARAs (FY2022 restated in RMB). FY2021 revenue, gross profit, net profit and diluted EPS come from the FY2025 AR five-year highlights. The other FY2021 lines are converted from FY2021 AR HK$ figures (S&D HK$16.7m, admin HK$92.8m, finance costs HK$22.6m, tax HK$33.7m, attributable HK$103.6m) at RMB0.830/HK$, with operating profit derived as PBT plus net finance cost.

FY2022 DPS is HK2c interim plus HK3c final.

Margins and growth

Revenue CAGR FY2021–FY2025: −1.6% p.a. (computed: 965.6 → 904.7). In HK$ terms, revenue was HK$887.2m in FY2020 and HK$1,163.1m in FY2021.

Revenue and gross profit — trends and drivers.

FY2022: Revenue peaked as post-COVID restocking and natural-resource inflation drove carrageenan prices sharply higher (carrageenan revenue +65.7%).

FY2023: Customers cut safety stocks and European demand slowed, so carrageenan prices fell. Export volumes of carrageenan and agar dropped 20.7%. The group was holding seaweed bought at peak prices, which forced a RMB142.4m net-realisable-value provision. Gross margin collapsed to 3.2%; excluding the provision it would have been 15.3%, per management.

FY2024: RMB131.8m of the prior provision was released as the underlying inventory was sold, which flattered gross margin (22.5%) and turned the group profitable.

FY2025: Seaweed and carrageenan prices kept falling. Refined carrageenan volume fell 10.7% and ASP 5.1%; agar volume fell 13.3% and ASP 1.4%. Gross margin slipped to 18.5% and net income almost disappeared.

Operating costs.

  • Opex rose every year: S&D +86% and admin +21% from FY2022 to FY2025. Drivers were overseas sales hires, trade shows, salary increments and R&D materials for algae membranes.

  • This creates negative operating leverage in a falling-price environment.

  • Finance costs peaked at RMB40.9m in FY2023 as HKD/USD rates rose, and have eased with lower RMB rates (weighted average rate 4.59% FY2022 → 5.73% FY2023 → 5.22% FY2024 → 4.57% FY2025).

Balance sheet

Sources: FY2025, FY2024 and FY2023 ARAs. FY2021 is the restated RMB balance sheet at 1 Jan 2022 from the FY2023 ARA. FY2024 and FY2025 long-term borrowings include unsecured third-party loans of RMB17.0m and RMB18.4m respectively. No separately disclosed goodwill line exists; the intangible assets line is shown.

Commentary.

Asset quality: The balance sheet is dominated by inventory: RMB838.3m, 51% of total assets and 75% of current assets at FY2025. Inventory has stayed far above pre-2022 levels despite three years of falling revenue.

Funding structure: Debt is short-dated and bank-funded: 84% of borrowings are due within 12 months, all at variable rates. Some debt is secured on land and buildings (carrying value RMB81.4m) and guaranteed by the Chairman (RMB70.3m unsecured facilities guaranteed by Chan Kam Chung and RMB10.0m by Guo Dongxu).

Covenants: In December 2025 the group needed one-time covenant waivers on RMB125.6m of debt. The auditor-approved accounts include an explicit going-concern basis-of-preparation note relying on continued waivers and facility renewals.

Cash flow

Sources: FY2025 ARA going-concern note (cash inflow from operations RMB128.7m in FY2024 and RMB7.0m in FY2025); capex from FY2023–FY2025 ARAs; FY2021 capex HK$77.5m converted.

1H2026: net operating cash flow RMB123m (+739.5% YoY), financing −RMB53.0m, investing −RMB2.1m (1H2026 report summary).

Commentary. Cash generation is highly sensitive to inventory build.

  • FY2025's RMB90.6m inventory increase absorbed almost all operating cash.

  • In 1H2026 inventory fell 7.7% and operating cash flow recovered to RMB123m. Part of this went to cut short-term debt (−6%) and long-term debt (−9.9%), and cash rose 55.8%.

  • No buyback programme exists beyond small trustee purchases for the share award scheme.

Ratios (computed, year-end basis)

Notes: FY2023 DIO is understated because cost of sales includes the RMB142.4m provision. Net debt/EBITDA is not meaningful for FY2023 (negative EBITDA). Company-reported gearing for FY2021 (36.0%) is as reported in HK$.

Ratio commentary.

  • Returns have structurally fallen from the FY2022 super-cycle: ROIC went from 15.6% to 2.0%.

  • Leverage worsened sharply on an earnings basis (net debt/EBITDA 5.8x; interest cover 1.2x) even though book gearing looks stable. This is what triggered the covenant waivers.

  • The cash conversion cycle of almost 400 days is extreme even for a seaweed processor, which must buy harvests seasonally. It is the single most important balance-sheet risk.

  • The 1H2026 report shows some relief: liabilities/assets 47.4%, interest-bearing debt/assets 34.5%, current ratio 1.71, quick ratio 0.5.

Interim snapshot

1H2026 gross profit is computed from the reported 14.16% margin. 1H2026 net profit is approximate, from the −0.56% net margin.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (CNY Mn)

Segment revenue (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Agar-agar

241.9322.0298.7294.9252.1

Carrageenan

569.3943.6708.3487.3410.6

Konjac products

57.746.242.557.588.7

Blended products

71.293.5124.3138.4138.5

Others

25.55.60.211.114.8

Total revenue

965.61,410.91,174.0989.3904.7

Segment gross profit (CNY Mn)

Segment gross profit (CNY Mn)FY2022FY2023FY2024FY2025

Agar-agar

100.693.188.272.4

Carrageenan

245.8-96.882.938.8

Konjac products

5.14.77.513.3

Blended products

31.636.739.437.6

Others

1.00.04.45.2

Total gross profit

384.137.6222.5167.2

Segment gross margin (%)

Segment gross margin (%)FY2022FY2023FY2024FY2025

Agar-agar

31.231.229.928.7

Carrageenan

26.1-13.717.09.4

Konjac products

11.111.013.114.9

Blended products

33.829.528.527.2

Group

27.23.222.518.5

Segment YoY revenue growth (%)

Segment YoY revenue growth (%)FY2022FY2023FY2024FY2025

Agar-agar

33.1-7.2-1.3-14.5

Carrageenan

65.7-24.9-31.2-15.7

Konjac products

-19.9-8.035.354.3

Blended products

31.333.011.30.0

Group

46.1-16.8-15.7-8.6

Segment share of revenue (%)

Segment share of revenue (%)FY2021FY2022FY2023FY2024FY2025

Agar-agar

25.122.825.429.827.9

Carrageenan

59.066.960.349.345.4

Konjac products

6.03.33.65.89.8

Blended products

7.46.610.614.015.3

Others

2.60.40.01.11.6

Segment revenue (CNY Mn) (1H2025–1H2026)

Segment revenue (CNY Mn)1H20251H2026

Carrageenan

186.1278.0

Agar-agar

124.7129.0

Blended products

55.368.6

Konjac products

35.952.9

Others

8.06.1

Total

410.0535.0

Income Statement and Per-Share Data

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

965.61,410.91,174.0989.3904.7

Cost of sales

741.11,026.81,136.4766.8737.5

Gross profit

224.5384.137.6222.5167.2

Selling & distribution expenses

13.913.817.820.625.9

Administrative expenses

77.091.197.3104.6110.5

Operating profit

132.8289.2-72.4110.234.6

D&A (land use rights, PP&E, intangibles)

—49.546.848.047.4

EBITDA (computed)

—338.7-25.6158.282.0

Finance costs

18.827.740.930.127.7

Pre-tax income

114.2261.6-112.980.97.1

Income tax

28.061.7-27.420.01.8

Net income

86.3199.9-85.460.95.4

Net income attributable to owners

86.0199.2-85.362.26.6

EPS basic (MYR Bn)

—0.242-0.1030.0740.008

EPS diluted (MYR Bn)

0.1020.240-0.1030.0740.008

Dividend per share (HK cents)

—5.00.01.21.2

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth YoY

—46.1-16.8-15.7-8.6

Gross margin

23.227.23.222.518.5

Operating margin

13.820.5-6.211.13.8

EBITDA margin

—24.0-2.216.09.1

Net margin

8.914.2-7.36.20.6

Effective tax rate

24.523.624.324.724.6

Balance Sheet

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

1,389.61,691.01,543.61,572.31,632.3

Property, plant & equipment

412.2401.4374.9372.9362.1

Land use rights

55.954.953.952.650.8

Intangible assets (incl. any goodwill)

72.467.966.967.163.7

Inventories

562.1906.2785.0747.7838.3

Trade & other receivables

162.6208.3127.3149.5166.8

Cash & equivalents (unrestricted)

109.437.772.6120.788.6

Restricted cash

0.01.111.720.719.7

Short-term borrowings

408.9491.3532.0460.6488.9

Long-term borrowings

77.088.667.2101.096.1

Total borrowings

486.0579.9599.1561.6585.0

Lease liabilities

6.64.52.93.57.8

Net debt (borrowings − cash − restricted cash)

376.6541.2514.8420.2476.6

Total equity

704.7852.2754.1850.1847.1

Equity attributable to owners

688.4844.6745.2839.9838.7

Current assets

838.61,153.3996.71,038.71,113.5

Current liabilities

575.0723.0697.1595.8663.0

Working capital (net current assets)

263.6430.3299.6442.9450.5

Cash Flow and Balance Sheet

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Cash generated from operations

———128.77.0

Capital expenditure

64.343.411.848.047.4

Free cash flow (computed: operations − capex)

———80.7-40.4

Dividends paid

—32.122.40.09.5

Share purchases by award trust (HKD Mn)

0.30.00.50.01.1

New equity issued (HKD Mn net)

0.00.00.032.30.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%) attributable NI / year-end attributable equity

12.523.6-11.47.40.8

ROA (%) NI / total assets

6.211.8-5.53.90.3

ROIC (%) OP×(1−25%) / (equity + net debt)

9.215.6-4.36.52.0

Current ratio (x)

1.461.601.431.741.68

Debt / equity (x)

0.690.680.790.660.69

Gearing per company (%) net debt / (net debt + equity)

36.039.141.234.337.3

Net debt / EBITDA (x)

—1.6—2.75.8

Interest coverage (x) OP / finance costs

7.110.4-1.83.71.2

Asset turnover (x)

0.690.830.760.630.55

Days inventory outstanding

277322252356415

Days sales outstanding (trade receivables)

—39274249

Days payables outstanding (trade payables)

—49334466

Cash conversion cycle (days)

—312246354398

Income Statement and Margin Analysis (%)

Metric (CNY Mn)1H20231H20241H20251H2026

Revenue

582.9459.0410.0535.0

Gross profit

106.198.860.175.8

Gross margin (%)

18.221.514.714.2

Net profit

25.122.6-12.3-3.0

Attributable profit

25.0—-12.1-1.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Region revenue (CNY Mn)

Region revenue (CNY Mn)FY2022FY2023FY2024FY2025

Chinese Mainland

582.9595.2475.2434.9

Europe

470.7291.6286.2235.1

Asia excluding Chinese Mainland

237.9209.8161.7161.7

South America

62.650.642.147.8

North America

52.423.620.620.4

Africa

4.23.03.24.6

Oceania

0.10.10.20.1

Total

1,410.91,174.0989.3904.7

Region YoY growth (%)

Region YoY growth (%)FY2023FY2024FY2025

Chinese Mainland

2.1-20.2-8.5

Europe

-38.0-1.9-17.8

Asia excluding Chinese Mainland

-11.8-22.90.0

South America

-19.1-16.913.6

North America

-54.9-12.7-1.1

Africa

-29.48.143.1

Region share of revenue (%)

Region share of revenue (%)FY2021FY2022FY2023FY2024

Chinese Mainland

47.941.350.748.0

Overseas

52.158.749.352.0

Region non-current assets (CNY Mn)

Region non-current assets (CNY Mn)FY2022FY2023FY2024FY2025

Chinese Mainland

448.2423.5424.7413.9

Hong Kong

1.20.41.50.9

Indonesia

76.375.270.763.5

Share Price History

DatePrice (HKD)Context / source

17 Oct 2019

1.16

IPO price

Early Dec 2022

3.54

Close before 5 Dec 2022 share-award grant (FY2025 AR) — near the cycle peak

20 May 2024

0.77

Close before 21 May 2024 share-award grant

5 Aug 2024

0.78

Close before placement (placed at HK$0.81)

30 Dec 2025

0.62

ET Net quote

23 Feb 2026

0.64

ET Net quote

17 Jul 2026

0.72

Google Finance (market cap HK$629m; 52-week range 0.57–0.79)

31 Jul 2026

0.68

StockAnalysis quote

Return metric (%)

1-year

3-year

Share price change

-12.5-82.4

Valuation Snapshot

MultipleValueBasis

P/E (TTM)

28.4x

28 Sep 2026 close (10jqka / CSJ). TTM attributable profit ≈ RMB17.3m (computed)

P/B

0.59x

28 Sep 2026

P/S (TTM)

0.48x

28 Sep 2026

EV/Sales (FY2025)

~1.1x

Computed: market cap ~RMB490m + FY2025 net debt RMB476.6m + NCI RMB8.4m ≈ RMB975m

EV/EBITDA (FY2025)

~11.9x

Computed: EV ~RMB975m / EBITDA RMB82.0m

Dividend yield

~1.7–1.9%

HK1.2c on a HK$0.62–0.72 price

Dividend (HK cents/share)

Dividend (HK cents/share)FY2021FY2022FY2023FY2024FY2025

Interim

—2.00.00.00.0

Final

2.53.00.01.21.2

Total cash paid in year (CNY Mn)

—32.122.40.09.5

Debt maturity (CNY Mn, 31 Dec 2025)

Debt maturity (CNY Mn, 31 Dec 2025)Amount

Bank borrowings due within 1 year

488.9

Bank borrowings due after 1 year

77.8

Third-party loan (unsecured, fixed rate) due after 1 year

18.4

Lease liabilities — within 1 year

1.8

Lease liabilities — after 1 year

6.0

Total borrowings and leases

592.8

Analyst Conclusions

Management guidance

There is no numeric guidance. Qualitative outlook (FY2025 AR, 30 Mar 2026):

  • carrageenan prices to bottom out and gradually rise;

  • PRC sales to improve;

  • the blended-product uptrend to continue;

  • continued investment in PT Hongxin;

  • strong long-term demand for hydrocolloids across food, household, skincare and biodegradable seaweed products.

The 12 Aug 2026 update attributes 1H2026 improvement to carrageenan volume gains from a competitive pricing strategy.

Consensus

Not available (no coverage identified).

Bull case

  1. Cyclical trough and operating leverage. 1H2026 revenue rose 30.5% to RMB535m while the attributable loss narrowed to RMB1.4m. If carrageenan prices stabilise while volumes hold, every 5 points of gross margin on a ~RMB1.0–1.1bn run-rate adds about RMB50m of gross profit. That is roughly ten times FY2025 net profit.

  2. Inventory release and deleveraging. Inventory fell 7.7% in 1H2026 and operating cash flow reached RMB123m. Continuing to bring the ~400-day cash conversion cycle back toward FY2023's ~250 days could release more than RMB200m of cash, reduce net debt/EBITDA below 3x and remove covenant risk.

  3. Deep value with option value. The stock trades at 0.59x book. On top of the core business, there are unpriced options in agarose microspheres and certified biodegradable films, the latter backed by a local-government investor.

Bear case

  1. Structural price deflation, not a cycle. Carrageenan ASPs fell for three consecutive years, and 1H2026 volume was bought with price (gross margin 14.2%, below FY2025's 18.5%). Domestic "involution" may keep margins structurally low.

  2. Refinancing fragility. 84% of debt is current, interest cover is 1.2x (FY2025), covenant waivers were needed, and the accounts carry a going-concern note. A bank pulling facilities in a weak half could force dilutive equity or distressed inventory sales.

  3. Governance and minority-shareholder risk. The controlling family holds 67%, the Chair/CEO roles are combined, there is no research coverage, liquidity is thin, distributable reserves are only RMB77.2m, and there is a prior Model Code breach. These factors argue for a persistent discount regardless of operational recovery.

Catalysts and monitorables (next 12 months)

  • FY2026 annual results (expected around late March 2027): full-year profitability, gross-margin trajectory and dividend.

  • Whether covenant waivers recur at end-FY2026, and the terms of facility renewals.

  • Seaweed and carrageenan price indicators (Indonesia and Philippines) and European demand.

  • Inventory and DIO trend; operating cash flow in 2H2026.

  • First disclosed revenue from algae membrane or agarose microspheres; Blue Ocean funding milestones.

  • PT Hongxin capacity expansion and capex.

  • The outcome of Ingredion's proposal for Tate & Lyle and its implications for global pricing.

  • Any change in the controlling shareholders' stakes, or a privatisation proposal (speculative; none announced).

Analyst verdict

Green Fresh Biotechnology is a genuine scale player in a niche but essential ingredient chain. It is China's largest agar and refined/semi-refined carrageenan producer by its commissioned rankings, with a cost-advantaged Indonesian plant and a credible portfolio of adjacent higher-value products. Yet the FY2021–FY2026 record shows a business whose economics are governed by seaweed prices and inventory timing rather than by pricing power or proprietary technology.

The FY2022 windfall (net profit RMB199.9m) was followed by a provision-driven loss in FY2023. FY2024's flattering recovery was itself partly an accounting release of earlier provisions. FY2025's near-zero profit (RMB5.4m) is the cleaner read on underlying earnings power in a deflationary market.

The balance sheet is the crux. Almost RMB840m of inventory sits against RMB585m of mostly short-term bank debt. Covenant waivers and a going-concern note mean the equity is effectively an option on management's ability to turn inventory into cash while banks keep rolling facilities.

The 1H2026 data are the first encouraging sign in two years: 30% revenue growth, a near-breakeven result and RMB123m of operating cash flow. They also confirm that the recovery is volume bought through price, with gross margin at 14.2%.

At 0.59x book and about 1.1x EV/sales, the market is pricing persistent sub-par returns plus some refinancing risk, and that is defensible. A re-rating requires three things together:

  • carrageenan margins recovering to the high teens;

  • a durable cut in inventory days to below 300;

  • visible revenue from the agarose and algae-membrane bets.

Until at least two of these are evident in FY2026 results, the stock is best viewed as a speculative, cyclical deep-value situation with elevated balance-sheet and governance risk. Stance: Neutral / Speculative Hold, with balance-sheet monitorables as the primary trigger for revision.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAgeWith group sinceBackground / prior rolesEducation

CHAN Kam Chung

Executive Director, Chairman & CEO; chairs Nomination Committee; member of Remuneration Committee

55

May 2003

Director/Deputy GM of Guangda (Fujian) Foodstuff (1998–2001); honorary president of China Algae Industry Association Carrageenan Branch (2019)

Part-time food-technology courses, Zhangzhou Institute of Technology (2013); HKU SPACE executive programme (2016)

GUO Dongxu

Executive Director, Vice Chairman & Vice President (project development, QC, external affairs)

58

Mar 2009

Executive director, South Fujian Agar Co. (1995–2018); GM of Lvqi (Fujian); president of China Algae Industry Association Carrageenan Branch (2019)

Part-time courses, Zhangzhou Institute of Technology

CHAN Shui Yip

Executive Director, Vice Chairman & Vice President (product management, sourcing, HR, administration)

64

Mar 1999

Deputy manager, Jinjiang Xinyi Leather & Plastic (1988–1999). Elder brother of Chan Kam Chung

PKU Shenzhen advanced business administration (2017); Renmin University finance course (2018)

SHE Xiaoying

Executive Director (sales)

64

May 2003

Production manager, Jinjiang Xinyi (1988–2003); former GM of Green Fresh (Fujian). Brother-in-law of both Chans

—

CHEN Yi (Ms.)

Executive Director (from 7 Jun 2024); VP (Management: HR, admin, IT)

38

May 2019

HR & admin manager, AB InBev Sedrin (Zhangzhou) Brewery (2011–2019)

BA Fujian Agriculture & Forestry University (2011); MBA Hongkong Finance & Economics College (2022)

HO Kwai Ching, Mark

INED; chairs Audit Committee

64

Listing (2019)

Ex-HKEX VP Corporate Strategy; ex-COO Oriental Patron Securities; CEO of ProMEX; INED of Lee Kee, Hengan International, Everbright Grand China Assets (from 19 Nov 2025)

BSocSc HKU (1984); FCCA, FHKICPA

NG Man Kung

INED; chairs Remuneration Committee

74

Listing (2019)

Chief executive of Chiyu Banking Corp (1992–2012); INED of Fujian Holdings and ELL Environmental

Banking extension course, HK PolyU

HU Guohua

INED; Audit Committee and Nomination Committee (from 27 Jun 2025)

52

Listing (2019)

Hydrocolloid and food-additive specialist; Secretary General, Sweet Flavouring Committee (China Food Additives & Ingredients Assoc.); INED of Zhejiang Shengda Bio-pharm, Anhui JinHe, Touyun Biotech

BSc, MSc Nanchang University; PhD (Eng.) East China University of Science & Technology (2006)

“—” = not publicly disclosed.

Board & Management Changes

DateChange

17 Jul 2023

NED Guo Songsen resigned after an SFC enquiry revealed Model Code breaches (dealings in the 2022 and 2023 blackout periods)

7 Jun 2024

Ms. Chen Yi appointed Executive Director

27 Jun 2025

Chen Yi and Hu Guohua appointed to the Nomination Committee

19 Nov 2025

Ho Kwai Ching additionally appointed INED of Everbright Grand China Assets

Major Shareholders

HolderVehicleShares%

Chan Kam Chung

COS Kreation Investment Development Co.

161,700,00018.50

Chan Shui Yip

Epoch Investment Development Co.

161,700,00018.50

Guo Songsen

Green Forest (BVI) Investment Co. (plus 866,000 direct)

92,603,57110.59

Guo Dongxu

Strong Achievement (BVI) Investment Co.

66,150,0007.57

Guo Yuansuo

Winning Path Trading Co.

66,150,0007.57

Guo Donghuang

East Prosperity (BVI) Investment Co.

39,696,4294.54

Concert group total

—588,000,00067.27

Chen Yi (director)

Direct (incl. unvested awards)

818,0000.09

Share award trust

Trustee

~8.4m shares (book cost RMB8.4m); 6.53m available for grant

~0.75

Public float

—

≥25% confirmed

~32

Competitive Landscape

Key Competitors

CompetitorHQSegments competingRelative positioningRevenue (latest)

CP Kelco (part of Tate & Lyle since 15 Nov 2024)

US / UK

Carrageenan, pectin, specialty gums

Global premium texturant leader; applications labs; multinational customer base

Tate & Lyle FY Mar-2026 revenue £2,006m (CP Kelco revenue implied ~US$700m from the "10% = ~US$70m" synergy target)

Ingredion (bidder for Tate & Lyle, May 2026)

US

Texturants (starches, gums, via proposed T&L/CP Kelco combination)

Scale texturiser; potential mega-consolidator

—

IFF (Nourish)

US

Carrageenan and other texturants (legacy DuPont/FMC portfolio)

Global multinational supplier

—

Cargill (texturizing solutions)

US

Carrageenan, pectin, alginates

Global, vertically integrated

Private — not disclosed

Ceamsa

Spain

Carrageenan, pectin

European specialist

Private — not disclosed

Gelymar

Chile

Carrageenan

South American seaweed-integrated

Private — not disclosed

W Hydrocolloids / Shemberg / Marcel Carrageenan / TBK

Philippines

Carrageenan (refined and semi-refined)

Origin-based processors close to Eucheuma supply

Private — not disclosed

Ina Food Industry

Japan

Agar

Leading Japanese agar maker; premium

Private — not disclosed

Hispanagar / Iberagar / B&V Agar

Spain / Portugal / Italy

Agar, agarose (B&V in lab agar)

European agar specialists

Private — not disclosed

Fujian and Shandong regional peers (e.g., Shishi-based agar processors; Qingdao algae processors)

China

Agar, carrageenan

Domestic price competition ("involution")

—

Hubei-based konjac processors (e.g., Yizhi Konjac)

China

Konjac gum

Domestic konjac leaders

—

“—” = not publicly disclosed.

Competitive Advantages & Vulnerabilities

AdvantagesVulnerabilities

Scale in agar plus carrageenan (27,390 t capacity) and a dual seaweed-origin footprint (China + Indonesia)

Commodity exposure: earnings swing with seaweed prices; FY2023 loss

Low-cost Indonesian semi-refined carrageenan

Small R&D budget (RMB28.7m) vs multinationals

Breadth across four colloids enables blends

Balance-sheet stretch: 398-day CCC, net debt/EBITDA 5.8x, covenant waivers

Standards-setting role and HNTE status

Customer concentration modest, but supplier concentration high (top-5 suppliers 53%)

Quick-dissolve agar and agarose niches

Thin Western brand presence; North America only 2.3% of sales

Founder-aligned controlling shareholders (67%)

Weak governance optics: combined Chair/CEO, family board, prior Model Code breach

Peer Comparison FY2025

MetricGreen Fresh Bio (FY2025)Tate & Lyle incl. CP Kelco (FY Mar-2026)

Revenue

RMB904.7m (~US$126m, computed)

£2,006m

Revenue growth

−8.6%

+16% statutory; −3% pro forma

Gross margin

18.5%—

Net margin

0.6%—

R&D intensity

3.2%—

Recent Developments

--

Company Snapshot

$125.8M

Revenue

1,030

Employees

1999

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Scale leadership. Ranked No.1 in China for agar and refined/semi-refined carrageenan in 2020–21 and 2023–24 (Frost & Sullivan, March 2025; FY2025 AR).
  • Broad colloid platform. Four colloids plus blends; design capacity of 27,390 t across six bases (FY2025 AR).
  • Indonesian cost base. PT Hongxin's 4,300 t of semi-refined carrageenan capacity, acquired for HK$60m in 2021, offers lower operating cost and proximity to seaweed (FY2024 ARA).
  • Agar profitability. Agar segment gross margin held at 28.7–31.2% across FY2022–FY2025, including through the FY2023 crisis (ARAs).
  • Growth in higher-value lines. Blended product volume CAGR above 20% (2021–25); konjac revenue +54.3% in FY2025 with margin up to 14.9% (FY2025 ARA).
  • Cash flow can swing positive quickly. 1H2026 operating cash flow was RMB123m, up 7x, as inventory was released (12 Aug 2026 announcement; 1H2026 report).
  • Diversified customer base. Top-5 customers 24.9%; largest 8.0% (FY2025 AR).

Weaknesses

  • Commodity-driven earnings volatility. Net profit moved from RMB199.9m (FY2022) to −RMB85.4m (FY2023) to RMB60.9m (FY2024) to RMB5.4m (FY2025).
  • Bloated working capital. Inventory of RMB838.3m is 51% of assets; DIO is 415 days (computed, FY2025).
  • Leverage and liquidity. RMB488.9m of the RMB585.0m of borrowings are short-term; interest cover 1.2x; covenant waivers on RMB125.6m (FY2025 ARA).
  • Rising cost base on falling revenue. S&D +25.7% and admin +5.6% in FY2025 while revenue fell 8.6%.
  • Small R&D budget. RMB28.7m in FY2025 — insufficient to compete with multinational application labs at scale.
  • Governance. Combined Chair/CEO; family-dominated board; only three INEDs; the 2023 Model Code breach by a former NED.
  • Thin distributable reserves. RMB77.2m at end-FY2025; dividends are paid from share premium (FY2025 AR).

Opportunities

  • Carrageenan price recovery. Management expects prices to bottom out (FY2025 AR); 1H2026 carrageenan revenue already up 49%.
  • Biodegradable seaweed films. FDA, SGS and home-compostability validations completed in 2025 position the company for plastic-free packaging demand.
  • Biopharma agarose microspheres. In production since 2022; high-value niche.
  • Konjac health-fibre demand. Konjac has been the fastest-growing line.
  • South American growth. Revenue +13.6% in FY2025.
  • Industry consolidation. Ingredion's proposal for Tate & Lyle/CP Kelco may create pricing discipline or outsourcing and toll-manufacturing opportunities for low-cost Asian producers.
  • Local-government co-investment. Xinwan Investment's RMB63.85m commitment de-risks the funding of new materials.

Threats

  • Continued seaweed and carrageenan deflation. Refined carrageenan ASP fell 5.1% in FY2025 on top of the FY2023–FY2024 declines.
  • Domestic price wars. Management explicitly cites "involution" in China (FY2025 AR).
  • Bank refinancing risk. Going concern depends on continued waivers and facility renewals (FY2025 ARA note 2.1).
  • Trade policy. The 2025 tariff war hit overseas demand; North American sales have fallen to RMB20.4m.
  • Regulatory scrutiny of carrageenan. Health concerns are cited as a restraint in industry reports.
  • Competitive scale-up. The CP Kelco–Tate & Lyle (and potentially Ingredion) combination concentrates customer relationships and R&D firepower.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Mar 2025Positive profit alert: FY2024 attributable profit expected at RMB50–70m vs RMB85.3m lossConfirmed the turnaround (context, just before the window)
Mar 2025Frost & Sullivan report: No.1 in PRC and globally for agar and refined/semi-refined carrageenan (2023–24); Forbes China innovation awardReputational support
31 Mar 2025FY2024 results: revenue RMB989.3m (−15.7%), net profit RMB60.9m; HK1.2c final dividend reinstatedReturn to profit and dividend
Apr 2025FY2024 annual report and ESG report publishedRoutine
May 2025Seaweed-based biodegradable product passes FDA food-contact safety assessmentKey gate for packaging commercialisation
22 May 2025Proposed change of name to Green Fresh Biotechnology announcedStrategic rebranding
6 Jun 2025AGM and EGM: FY2024 dividend approved; name change approved by special resolutionGovernance
10 Jun 2025Cayman certificate of change of name issued; FY2024 dividend ex-dateLegal effect of the name change
25 Jun 2025Scheduled payment date of FY2024 dividend per the dividend announcement. The FY2025 ARA says it was paid in July and October 2025 (discrepancy noted)Possible staggered cash payment; liquidity signal
27 Jun 2025Chen Yi and Hu Guohua appointed to the Nomination CommitteeGovernance
9 Jul 2025HK Companies Registry registers the new nameLegal
17 Jul 2025Change of company name and stock short name ("GREEN FRESH BIO") becomes effective on HKEXTrading identity
Aug 2025SGS 100% Bio-Based Certification for the seaweed filmProduct validation
8 Aug 2025Profit warning for 1H2025Earnings deterioration
28 Aug 20251H2025 results: revenue RMB410.0m (−10.7%); gross margin 14.7%; net loss RMB12.3m; no interim dividendReturn to loss
24 Sep 2025Executive directors' service contracts and INED appointment letters renewed (no fixed term)Governance continuity
Sep 20251H2025 interim report publishedRoutine
Oct 2025SGS No Plastic CertificationProduct validation
19 Nov 2025INED Ho Kwai Ching appointed to another listed board (Everbright Grand China Assets)Director time-commitment disclosure
Dec 2025One-time covenant waivers from banks on RMB125.6m of debt for FY2025Material credit event
Dec 2025Home-compostability compliance demonstratedProduct validation
17 Mar 2026Board-meeting notice for FY2025 resultsRoutine
30 Mar 2026FY2025 results: revenue RMB904.7m (−8.6%); net profit RMB5.4m; going-concern note; HK1.2c final dividendProfit collapse; liquidity scrutiny
24 Apr 2026FY2025 annual report, AGM notice, buyback and general mandate proposalsRoutine; buyback mandate (no buyback executed)
14 May 2026Industry: Ingredion makes a conditional proposal to acquire Tate & Lyle (owner of CP Kelco since Nov 2024)Consolidation among global competitors
12 Jun 2026AGM; retiring directors re-elected (poll results announced)Governance
16 Jun 2026FY2025 final dividend ex-date (payment on or around 15 Jul 2026)Shareholder return
12 Aug 2026Positive update: 1H2026 attributable loss expected at RMB1–4m (vs RMB12.07m); operating cash flow more than 7x higherRecovery signal; volume-led via competitive pricing
Late Aug 20261H2026 interim results announced (within the Listing Rules deadline per the 12 Aug notice)Confirms the update
29 Sep 20261H2026 interim report: revenue RMB535m (+30.5%); attributable loss RMB1.39m; operating cash flow RMB123m; headcount 1,030Inflection in volume and cash; margin still thin

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 965.6 Mn in FY2021 to CNY 904.7 Mn in FY2025.
Green Fresh Biotechnology Company Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue965.61,410.91,174989.3904.7
Cost of sales741.11,026.81,136.4766.8737.5
Gross profit224.5384.137.6222.5167.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.